Acute Invasive Aspergillosis is an acute infection or fungal growth, which arises due to Aspergillus fungus. Almost everyone comes in contact with the Aspergillus fungus as it is found on decaying vegetation and dead leaves, however, not everyone is susceptible to the infection. Aspergillosis is categorized into various types such as invasive aspergillosis, chronic pulmonary aspergillosis, allergic bronchopulmonary aspergillosis, allergic aspergillus sinusitis, aspergilloma, and cutaneous aspergillosis. Active invasive aspergillosis (IA) is a rare, opportunistic, and serious fungal infection, which affects immunocompromised patients or those suffering from lung diseases. Risk factors responsible for the development of invasive aspergillosis infection include weakened immune system, low white blood cell count, presence of lung cavities, asthma or cystic fibrosis, and long-term corticosteroid therapy. Commercially available drugs for the treatment of aspergillus infection include Voriconazole, Capsofungin, and Amphotericin B, among others.
Acute Invasive Aspergillosis Treatment Market Drivers
According to the Centers for Disease Control and Prevention, the epidemiology of invasive aspergillus infection is dependent upon increasing number of solid organ transplants, stem cell transplant, and newer immunosuppressive agents, 2017. According to Organ Procurement and Transplantation Network (OPTN), around 8,500 organ transplants have been performed in 2018 and the number is expected to grow in the near future. These factors are expected to support the growth of the acute invasive aspergillosis treatment market. Patients who undergo organ transplant procedure are often prescribed immunosuppressant medications, which increases their susceptibility to aspergillosis infection. Similarly, patients in the advanced stages of AIDS are also highly susceptible to opportunistic infections such as aspergillosis. According to the World Health Organization (WHO), around 36.7 million people were found suffering from HIV in 2016. Extended use of corticosteroids further weakens the immune system, thus increasing the risk of developing such infections. This in turn, is increasing the demand for acute invasive aspergillosis treatment over the forecast period. According to British Infection Association, the high risk population for invasive aspergillosis includes patients who have undergone allogeneic hematopoietic stem cell transplantation (HSCT), autologous HSCT patients, solid organ transplant patients as well as AIDS patients, patients suffering from acute myeloid leukaemia, chronic lymphocytic leukaemia, chronic myeloid leukaemia, non-Hodgkin lymphoma, and myeloma patients. According to WHO, Cancer is the second-leading cause of death globally, and the disease caused 8.8 million deaths in 2015. Rising incidence of various types of cancers, is in turn expected to support growth of the global acute invasive aspergillosis treatment market.
The U.S. Food & Drug Administration (FDA) is increasingly approving several drugs for the treatment of this infection. For instance, Isavuconazonium, a prodrug form of Isavuconazole was approved by the FDA in 2015. Astellas Pharma US, Inc. markets Isavuconazonium under the brand name Cresemba. Astellas Pharma partnered with Basilea Pharmaceutica International Ltd. for license, co-development, and co-promotion of Isavuconazole (Cresemba), in 2010. In 2014, Basilea Pharmaceutica International Ltd. received full rights to sell Isavuconazole in all markets outside of the U.S. and Canada, and Astellas Pharma responsible for U.S. and Canada markets. Moreover, Basilea Pharmaceutica Ltd. partnered with Asahi Kasei Pharma for Isavuconazole development, licensing, and marketing in Japan (responsibility of Asahi Kasei), in 2016. The global acute invasive aspergillosis treatment market is expected to be significantly impacted over the forecast period as the drug Cresemba will expire in 2020. As generic manufacturers enter the market, the prices are expected to drop and volumes are expected to increase over the forecast period.
However, drug resistance to antifungal medications is widely witnessed during treatment of aspergillosis infections, which is expected to restrain growth of the acute invasive aspergillosis treatment market over the forecast period.
Acute Invasive Aspergillosis Treatment Market Insights
Most antifungal medications have lost their patent protection over the last few years and generic versions of these products are increasingly being made available by generic drug manufacturers, which in turn is supporting growth of the acute invasive aspergillosis treatment market. Manufacturers such as Amneal Pharmaceuticals, Sandoz Inc., Glenmark Pharmaceuticals Ltd., Mylan Pharmaceuticals, Inc., and Teva Pharmaceuticals offer generic versions of antifungal medications in the acute invasive aspergillosis treatment market. Independent organizations are dedicated towards research and development of novel antifungal therapies. For instance, F2G, an established U.K.-based biotechnology company is focused on the discovery and development of novel drugs for the treatment of serious fungal diseases such as acute invasive aspergillosis.
Key players operating in the global acute invasive aspergillosis treatment market include GlaxoSmithKline, Mylan Pharmaceuticals, Inc., Novartis AG, Abbott laboratories, Eli Lilly and Company, AstraZeneca Plc, Pfizer, Inc., Johnson & Johnson, Takeda Pharmaceutical Company Ltd., Astellas, and Basilea Pharmaceutica International Ltd.
Acute Invasive Aspergillosis Treatment Market Taxonomy-
Global acute invasive aspergillosis treatment market is segmented on the basis of drug type, distribution channel, and geography.
By Drug Type-
By Distribution Channel-
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.